Drugmakers Saw Robust ROI and Lower Development Costs in 2021, Says Analysis Post author:PacConAdmin Post published:January 12, 2022 Post category:Drug Industry Daily It’s been a banner year for the financial side of the pharmaceutical industry. Source: Drug Industry Daily You Might Also Like FDA Clarifies the Relief GDUFA II Gives to Small Businesses January 26, 2017 FDA Moves Against Cesium Chloride As Bulk Substance in Compounded Drugs July 23, 2018 Indivior to Acquire Overdose-Reversal Drugmaker Opiant Pharmaceuticals November 14, 2022